DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA INC

EIN: 208774179 501(c)(3) Health Care

NEW YORK, NY

Total Revenue
$6,221,917
Total Expenses
$6,349,740
Total Assets
$2,501,704
Net Assets
$976,702
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
2007
Legal Domicile
DE
Principal Officer
DARIN PORTNOY
Phone
6462157076
Tax Period
2024-01-01 to 2024-12-31

DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA INC, founded in 2007, is a community nonprofit in the Health Care sector that reported $6.2M in total revenue in fiscal year 2024. Revenue surged 43% from the prior year, signaling strong growth momentum.

Mission

THE MISSION OF DNDI NORTH AMERICA IS TO CONTRIBUTE TO THE ACHIEVEMENT OF DNDI'S GLOBAL OBJECTIVES, IN PARTICULAR TO STRENGHTEN AND EXPAND DNDI'S SCIENTIFIC, POLICY ADVOCACY, FUNDRAISING, AND COMMUNICATIONS EFFORTS IN NORTH AMERICA BY (A) PROVIDING FOCUSED SUPPORT FOR SPECIFIC R&D PROJECTS AND BUSINESS/PARTNER DEVELOPMENT ACTIVITIES IN NORTH AMERICA;(B) ACHIEVING CONCRETE POLICY CHANGES IN NORTH AMERICA TO CREATE A MORE FAVORABLE ENVIRONMENT FOR NEEDS-DRIVEN R&D FOR NEGLECTED DISEASES;(C) MOBILIZING PUBLIC AND PRIVATE FUNDS IN NORTH AMERICA TO SUPPORT DNDI'S MISSION;(D) INCREASING DNDI'S PROFILE AND VISIBILITY IN NORTH AMERICA, THEREBY DRAWING GREATER PUBLIC ATTENTION TO THE NEED FOR NEGLECTED DISEASE R&D.

Program Service Accomplishments

Program 1
Expenses: $5,117,384

GRANTS TO RESEARCH AND DEVELOPMENT FOR NEGLECTED DISEASES: DNDI NORTH AMERICA RAISES FUNDS TO SUPPORT DNDI'S RESEARCH AND DEVELOPMENT (R&D) ACTIVITIES IN ORDER TO CONTRIBUTE TO THE ACHIEVEMENT OF...

Read more

GRANTS TO RESEARCH AND DEVELOPMENT FOR NEGLECTED DISEASES: DNDI NORTH AMERICA RAISES FUNDS TO SUPPORT DNDI'S RESEARCH AND DEVELOPMENT (R&D) ACTIVITIES IN ORDER TO CONTRIBUTE TO THE ACHIEVEMENT OF DNDI'S GOAL OF DELIVERING 25 NEW TREATMENTS FOR NEGLECTED PATIENTS BY 2028 AND ESTABLISHING A ROBUST PIPELINE OF NEW POTENTIAL DRUG CANDIDATES. DNDI NOW HAS OVER 30 PROJECTS IN ITS PIPELINE, INCLUDING OVER 20 POTENTIAL NEW CHEMICAL ENTITIES (NCES), AND HAS DELIVERED 12 TREATMENTS OFR SIX DEADLY DISEASES THAT ARE ALREADY IN THE HANDS OF MILLIONS OF PATIENTS.

Program 2

RAISING PUBLIC AWARENESS AND ADVOCATING FOR NEGLECTED DISEASE R&D:AS PART OF ITS MISSION, DNDI ADVOCATES FOR ENHANCED POLITICAL LEADERSHIP, INCREASED RESOURCES, AND AN ENABLING POLICY ENVIRONMENT TO...

Read more

RAISING PUBLIC AWARENESS AND ADVOCATING FOR NEGLECTED DISEASE R&D:AS PART OF ITS MISSION, DNDI ADVOCATES FOR ENHANCED POLITICAL LEADERSHIP, INCREASED RESOURCES, AND AN ENABLING POLICY ENVIRONMENT TO STIMULATE R&D FOR NEGLECTED DISEASES. DNDI NORTH AMERICA ACTIVELY ADVOCATES FOR SOUND POLICIES, PARTICULARLY IN THE UNITED STATES, THAT WILL ENABLE GREATER NEEDS-DRIVEN R&D, INCLUDING APPROPRIATE INCENTIVES AND FINANCING MECHANISMS, INNOVATIVE REGULATORY PATHWAYS THAT EXPEDITE ACCESS, AND OPEN INNOVATION APPROACHES TO INTELLECTUAL PROPERTY MANAGEMENT THAT ENSURE THE WIDEST POSSIBLE SHARING OF RESEARCH KNOWLEDGE AND DATA.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $6,193,831
Program Service Revenue $0
Investment Income $28,086
Other Revenue $0
TOTAL REVENUE $6,221,917

Expense Breakdown

Grants Paid $3,670,704
Salaries & Benefits $1,745,876
Fundraising Expenses $589,388
Program Expenses $5,117,384
Other Expenses $933,160
TOTAL EXPENSES $6,349,740

Year-over-Year Comparison

2024 2023 Change
Revenue $6,221,917 $4,350,936 +0.4%
Expenses $6,349,740 $4,172,304 +0.5%
Net Income $-127,823 $178,632 -1.7%
Key Indicators
Grants to Organizations Grants to Individuals Lobbying Political Activity Foreign Activities Donor Advised Fund Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
8
Independent Members
8
Employees
12
Volunteers
12

Governance Policies

Conflict of Interest Policy
Whistleblower Policy
Document Retention Policy

Special Practices & Reported Activities

Operated a School
Operated a Hospital
Provided First Class Travel
Reported Conflict of Interest
Reported Asset Diversion
Excess Benefit Transaction
Made Political Expenditures
Engaged in Lobbying
Operated Donor Advised Fund
Maintained Art Collections
Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
5
$592,831
Total Directors
8
$0
Key Employees
0
$0
Highest Compensated
4
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
LUIS PIZARRO BOARD MEMBER 2.00
Director
$0 $0 $0
MEENA AHAMED BOARD MEMBER 2.00
Director
$0 $0 $0
AFRICA STEWART BOARD MEMBER 2.00
Director
$0 $0 $0
BENNETT SHAPIRO BOARD MEMBER 2.00
Director
$0 $0 $0
KRISTINA TORGESON BOARD MEMBER 2.00
Director
$0 $0 $0
DARIN PORTNOY CHAIR OF THE BOARD 3.00
Officer Director
$0 $0 $0
SHING CHANG SECRETARY 2.00
Officer Director
$0 $0 $0
JOHN LAWRENCE TREASURER 2.00
Officer Director
$0 $0 $0
DELALI ATTIPOE EXECUTIVE DIRECTOR 40.00
Officer
$239,914 $71,070 $310,984
RACHEL COHEN SENIOR ADVISOR, GLOBAL POL 40.00
Officer
$213,183 $68,664 $281,847
ILAN MOSS HEAD OF MEDIA AND CONTENT 40.00
Highest
$156,476 $13,940 $170,416
VISHAL GOYAL SENIOR CLINICAL PROJECT AN 40.00
Highest
$146,409 $31,015 $177,424
SHIRLEY LEUNG SENIOR HR BUSINESS PARTNER 40.00
Highest
$106,712 $44,282 $150,994
RON SYKES SENIOR INDIVIDUAL GIVING MANAGER 40.00
Highest
$123,284 $28,363 $151,647
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2024 $6,221,917 $6,349,740 $2,501,704 $-127,823
2023 $4,350,936 $4,172,304 $1,819,761 $178,632
2022 $3,931,942 $3,853,071 $1,155,455 $78,871
2021 $4,153,290 $3,993,581 $1,372,645 $159,709
2020 $3,738,262 $3,585,571 $1,506,481 $152,691
2019 $4,627,274 $4,593,537 $1,352,194 $33,737
2018 $5,843,041 $6,026,040 $2,330,609 $-182,999
Explore More Nonprofits
Top 100 Nonprofits in New York Largest U.S. Nonprofits Best Rated Nonprofits Most Efficient Nonprofits

Compare DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA INC with other nonprofits in New York and across the country.